BioPharma Resources

NDA 217469 · Harrow Eye

Vevye

Cyclosporine · Ophthalmic · Calcineurin Inhibitor Immunosuppressant

Last checked: Nov 19, 2026Latest source record: Sep 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

May 30, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,166

250 Phase 3, 65 recruiting

FAERS reports

6,159

85 serious, 5 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 26, 2026.

VEVYE indicated for the treatment of the signs and symptoms of dry eye disease. VEVYE (cyclosporine ophthalmic solution) 0.1% is a calcineurin inhibitor immunosuppressant indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 )

Mechanism: Cyclosporine, a calcineurin inhibitor, is a relatively selective immunomodulatory drug.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 30, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • VEVYE · CYCLOSPORINE 0.1% · SOLUTION, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cyclosporine" as an intervention, any sponsor and status, largest first.

All 1,166 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye irritation2,454
  • drug ineffective1,688
  • eye pain916
  • ocular hyperaemia538
  • vision blurred479
  • eye pruritus407
  • dry eye296
  • lacrimation increased272
  • ocular discomfort243
  • headache209
  • drug hypersensitivity205
  • eye swelling159

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20221
20232
2024974
20251,814
20263,368

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vevye (Cyclosporine)

2024 spending

$13.2M

Beneficiaries

5,877

15,393 claims

Per beneficiary

$2,249

$366.30 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$13,217,841

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,030 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.